Proactive Research analyst Daniel Appiah presents his latest report on Creo Medical.
The company develops and sells surgical devices for minimally invasive endoscopic surgery, mainly to remove suspected early-stage bowel cancers and to expand cases of a narrowed oesophagus.
Creo recently said it expects to report a half year-on-half year increase in revenue of over 10% to around £13.5mln.